Anticorps Polyclonaux Purifiés par Affinité à l’Antigène

Anti-Human VEGF165 (Polyclonal Rabbit)

0 ReviewsSubmit a Review

Product Details

Catalogue Number: 500-P10

Source: Polyclonal Rabbit

Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human VEGF 165. Anti-Human VEGF 165-specific antibody was purified by affinity chromatography employing an immobilized Human VEGF 165 matrix.

Immunogen: E.coli derived Recombinant Human VEGF165 (PeproTech catalog# 100-20)

Sandwich ELISA: To detect hVEGF by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech’s Biotinylated Anti-Human VEGF (500-P10Bt) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hVEGF.

Anti-Human VEGF 165 Sandwich ELISA Anti-Human VEGF 165 Sandwich ELISA

Western Blot: To detect hVEGF by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 µg/ml. Used in conjunction with compatible secondary reagents the detection limit for recombinant hVEGF is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.

Anti-Human VEGF 165 Western Blot Reduced Anti-Human VEGF 165 Western Blot Unreduced Anti-Human VEGF 165 Western Blot Reduced Anti-Human VEGF 165 Western Blot Unreduced


Additional applications tested on a lot-to-lot basis. Please contact Technical Support for more information.

Country Of Origin: USA

Not for human use.

Research Interest


First Author
Bottos, A
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.
Proceedings of the National Academy of Sciences of the United States of America; 109(6) pgE353-9
PubMed Id
First Author
Sluimer, J C
Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery.
Physiological Genomics; 30(3) pg335-41
PubMed Id
First Author
Baldewijns, M M
High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
British Journal of Cancer; 96(12) pg1888-95
PubMed Id